Assessment of AMPA receptor density in patients with schizophrenia: a cross-sectional [11C]K-2 PET study - AMPA PET study in patients with schizophrenia

Department of Physiology,Yokohama City University, School of Medicie0 个研究点目标入组 30 人开始时间: 2020年2月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) being pregnant or breast-feeding, or wishing to become pregnant, (2) being sensitive to alcohol, (3) comorbidity of serious neurological illness, (4) history of epilepsy, (5) use of perampanel or topiramate within 4 weeks, (6) history of substance use disorder for the past 6 months, (7) positive result on urine screening of substances that cause dependence, (8) having a metal object or pace maker in the body, (9) inappropriate size of head, neck, or body for MRI scan, (10) having large tatoo, (11) suffering from serious claustrophobia, (12) presence of significant brain anomaly, (13) abnormal lab results as follows: serum creatinine level of >=1.5, AST of >=150, or ALT of >=150, (14) having participated in any clinical trial that included the use of unapproved nuclear test within 6 months, (15) having participated in any other clinical trial that included intervention, (16) being judged to be inappropriate for participation by a study medical doctor

发起方

Department of Physiology,Yokohama City University, School of Medicie